NetraMark Holdings Inc. reported significant progress in Q2 2026, highlighting new strategic collaborations in oncology and neuroscience, including a partnership with Fondazione per la Medicina Personalizzata and a contract to analyze depression trial data. The company raised Cdn $3.5 million through a private placement and uplisted to the Toronto Stock Exchange, enhancing its market visibility. NetraMark's AI platform, NetraAI, continues to gain traction for its ability to improve clinical trial design and patient stratification, with a growing commercial pipeline and active proposals. Upcoming efforts include integrating NetraAI into clinical trial planning and expanding into psychedelic medicine research, supported by new clinical leadership appointments.
Blue Gold Limited announced that the Grand Court of the Cayman Islands ruled against implementing proposed amendments to the company's Articles of Association related to its 2025 business combination with Perception Capital Corp. IV. The court clarif...
Insigneo, a global wealth management firm, unveiled a refreshed brand identity emphasizing its growth and $33 billion in assets under management. The new tagline, "Your Passport to Possibilities," highlights Insigneo's role in connecting internationa...
SalesCloser Technologies has commissioned a dedicated AI inference cluster using NVIDIA Blackwell-class GPUs in Canada, enhancing its autonomous AI sales platform. This infrastructure allows custom fine-tuning of AI models on SalesCloser's sales data...
Cyabra, an AI-driven digital trust platform, announced its Q1 2026 results showing 12% revenue growth to $1.4 million and a 19% increase in annual recurring revenue to $7.0 million. The company recently went public on Nasdaq, marking a key milestone,...
Winnebago Industries announced a quarterly cash dividend of $0.35 per share, payable on June 24, 2026, to shareholders of record as of June 10, 2026. This dividend marks the company's 48th consecutive quarterly payment, reflecting confidence in its b...
